These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22022769)

  • 1. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
    Wehland M; Grosse J; Simonsen U; Infanger M; Bauer J; Grimm D
    Curr Vasc Pharmacol; 2012 May; 10(3):378-90. PubMed ID: 22022769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.
    Coats AJ
    Drugs Aging; 2006; 23(2):93-9. PubMed ID: 16536633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vasodilatory beta-blockers.
    Pedersen ME; Cockcroft JR
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
    Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Realities of newer beta-blockers for the management of hypertension.
    Manrique C; Giles TD; Ferdinand KC; Sowers JR
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR; Feuerstein GZ
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
    de Nigris F; Mancini FP; Balestrieri ML; Byrns R; Fiorito C; Williams-Ignarro S; Palagiano A; Crimi E; Ignarro LJ; Napoli C
    Nitric Oxide; 2008 Aug; 19(1):57-63. PubMed ID: 18435936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-thrombotic effects of nebivolol and carvedilol: Involvement of β2 receptors and COX-2/PGI2 pathways.
    Kozlovski VI; Lomnicka M; Bartus M; Sternak M; Chlopicki S
    Pharmacol Rep; 2015 Oct; 67(5):1041-7. PubMed ID: 26398401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J
    Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP; Giles TD; Sowers JR
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nephroprotective properties of third-generation beta-adrenoblockers].
    Kuz'min OB; Belianin VV; Zhezha VV
    Eksp Klin Farmakol; 2014; 77(3):40-3. PubMed ID: 24800526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.